Menu

Sign in

Sign in

Contact us

Homepage > Company > Media > Company news

Company news

Torrey Pines Investment's i2020 Accelerator to Advance Snap Bio's Selective Kinase Inhibitor Platform for Treatment of Endodermal Cancers and Autoimmune Diseases

Torrey Pines Investment's i2020 Accelerator to Advance Snap Bio's Selective Kinase Inhibitor Platform for Treatment of Endodermal Cancers and Autoimmune Diseases

SAN DIEGO, Nov.

Meet ChemDiv at 7th International Conference on Multicomponent Reactions and Related Chemistry

Meet ChemDiv at 7th International Conference on Multicomponent Reactions and Related Chemistry

Meet ChemDiv at 7th International Conference on Multicomponent Reactions and Related Chemistry which is to be held from August 26thto 31st2018at Heinrich Heine University (Dusseldorf, Germany)...

Meet ChemDiv at EFMC-ISMC’18 International Symposium on Medicinal Chemistry

Meet ChemDiv at EFMC-ISMC’18 International Symposium on Medicinal Chemistry

Join ChemDiv at EFMC-ISMC’18 on September 2-6, 2018 in Ljubljana, Slovenia.

ChemDiv Announces Expansion of Multi-Year Hit Identification Collaboration with Janssen

ChemDiv Announces Expansion of Multi-Year Hit Identification Collaboration with Janssen

SAN DIEGO, CA (January 23, 2018) –— ChemDiv, Inc.

Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6

Regen BioPharma, Inc.'s Medicinal Chemistry Program has Identified Additional Compounds That Activate NR2F6

Regen BioPharma, Inc.

ChemDiv, DZNE and Torrey Pines Investment Launch Inflammasome Discovery Program of Translational Collaboration on Neurodegeneration

ChemDiv, DZNE and Torrey Pines Investment Launch Inflammasome Discovery Program of Translational Collaboration on Neurodegeneration

SAN DIEGO and BONN, Jan.

Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS

Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS

Active Biotech (Nasdaq Stockholm.

ChemDiv, Context Therapeutics and Torrey Pines Investment Announce CNS Co-Development Agreement

ChemDiv, Context Therapeutics and Torrey Pines Investment Announce CNS Co-Development Agreement

- Sigma1 is a high-value oncology and neurodegenerative disease target- Together, the partners will run the first ever high-throughput Sigma1 screenSAN DIEGO, Nov.

ChemDiv’s Discovery Chemistry Platform to Help Advance Tri-Institutional Therapeutics Discovery Institute Programs

ChemDiv’s Discovery Chemistry Platform to Help Advance Tri-Institutional Therapeutics Discovery Institute Programs

SAN DIEGO, CA, November 6, 2017 – ChemDiv Inc.

Nature Communications Publishes a Study that Identified Small Molecule Which Imposes Metabolic Stress and Cellular Death in Malignant Cells

Nature Communications Publishes a Study that Identified Small Molecule Which Imposes Metabolic Stress and Cellular Death in Malignant Cells

On October 16, 2017 NATURE COMMUNICATIONS published an article named «A novel Fer/FerT targeting compound selectively evokes metabolic stress and necrotic death in malignant cells.

ChemDiv Achieves Milestone in Viriom Collaboration on Elsulfavirine/VM1500A Long Acting Injectable Formulation Development

ChemDiv Achieves Milestone in Viriom Collaboration on Elsulfavirine/VM1500A Long Acting Injectable Formulation Development

ChemDiv has reached a development milestone in partnership with Viriom Inc.

ChemDiv to Help Afraxis Advance Synaptic Profiling Platform for CNS Drug Discovery

ChemDiv to Help Afraxis Advance Synaptic Profiling Platform for CNS Drug Discovery

SAN DIEGO, October 5, 2017 – ChemDiv Inc.

1 2 3 456 7 8

0 items in Cart

Cart Subtotal:

You will be able to Pay Online or Request a Quote